JP2021514011A5 - - Google Patents

Info

Publication number
JP2021514011A5
JP2021514011A5 JP2020566549A JP2020566549A JP2021514011A5 JP 2021514011 A5 JP2021514011 A5 JP 2021514011A5 JP 2020566549 A JP2020566549 A JP 2020566549A JP 2020566549 A JP2020566549 A JP 2020566549A JP 2021514011 A5 JP2021514011 A5 JP 2021514011A5
Authority
JP
Japan
Prior art keywords
optionally substituted
membered
heteroaryl
heteroatoms selected
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020566549A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021514011A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/018774 external-priority patent/WO2019164949A1/en
Publication of JP2021514011A publication Critical patent/JP2021514011A/ja
Publication of JP2021514011A5 publication Critical patent/JP2021514011A5/ja
Pending legal-status Critical Current

Links

JP2020566549A 2018-02-20 2019-02-20 Ｅｇｆｒ阻害剤の組合せ医薬製剤およびその使用法 Pending JP2021514011A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862632806P 2018-02-20 2018-02-20
US62/632,806 2018-02-20
US201862744083P 2018-10-10 2018-10-10
US62/744,083 2018-10-10
PCT/US2019/018774 WO2019164949A1 (en) 2018-02-20 2019-02-20 Pharmaceutical combinations of egfr inhibitors and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2021514011A JP2021514011A (ja) 2021-06-03
JP2021514011A5 true JP2021514011A5 (https=) 2022-02-25

Family

ID=67688573

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020566549A Pending JP2021514011A (ja) 2018-02-20 2019-02-20 Ｅｇｆｒ阻害剤の組合せ医薬製剤およびその使用法

Country Status (6)

Country Link
US (1) US20210085688A1 (https=)
EP (1) EP3755337A4 (https=)
JP (1) JP2021514011A (https=)
AU (1) AU2019225807A1 (https=)
CA (1) CA3087797A1 (https=)
WO (1) WO2019164949A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210085688A1 (en) * 2018-02-20 2021-03-25 Dana-Farber Cancer Institute, Inc. Pharmaceutical combinations of egfr inhibitors and methods of use thereof
US11584746B2 (en) 2018-02-20 2023-02-21 Dana-Farber Cancer Institute, Inc. Inhibitors of EGFR and methods of use thereof
AU2019225799A1 (en) * 2018-02-20 2020-07-09 Dana-Farber Cancer Institute, Inc. Pharmaceutical combinations of EGFR inhibitors and methods of use thereof
CN110912796B (zh) 2018-09-15 2022-03-11 华为技术有限公司 一种通信方法、设备和系统
AU2022230397A1 (en) * 2021-03-02 2023-09-21 Dana-Farber Cancer Institute, Inc. Covalent egfr inhibitors and methods of use thereof
US20250197390A1 (en) * 2022-03-16 2025-06-19 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Fused heterocyclic compound, and preparation method therefor and medical use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007056388A2 (en) * 2005-11-07 2007-05-18 The General Hospital Corporation Compositions and methods for modulating poly (adp-ribose) polymerase activity
JP5752601B2 (ja) * 2008-12-08 2015-07-22 ブイエム ファーマ エルエルシー タンパク質受容体チロシンキナーゼ阻害薬の組成物
EP4119551A1 (en) * 2011-07-27 2023-01-18 Astrazeneca AB 2-(2,4,5-substituted-anilino)pyrimidine compounds
WO2014160430A1 (en) * 2013-03-13 2014-10-02 Georgetown University Small molecule lrrk2 and erk5 inhibitors
US20170114323A1 (en) * 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
TWI726968B (zh) * 2016-01-07 2021-05-11 開曼群島商Ｃｓ醫藥技術公司 Egfr酪胺酸激酶之臨床重要突變體之選擇性抑制劑
KR20180132812A (ko) * 2016-04-07 2018-12-12 다나-파버 캔서 인스티튜트 인크. 피리미도-디아제피논 키나아제 스캐폴드 화합물 및 ｐｉ3ｋ-매개된 장애의 치료 방법
CA3088561A1 (en) * 2018-02-20 2019-08-29 Dana-Farber Cancer Institute, Inc. Degraders of egfr and methods of use thereof
US20210085688A1 (en) * 2018-02-20 2021-03-25 Dana-Farber Cancer Institute, Inc. Pharmaceutical combinations of egfr inhibitors and methods of use thereof
US11584746B2 (en) * 2018-02-20 2023-02-21 Dana-Farber Cancer Institute, Inc. Inhibitors of EGFR and methods of use thereof
EP3755697A4 (en) * 2018-02-20 2021-10-27 Dana-Farber Cancer Institute, Inc. EGFR DEGRADATION AGENTS AND METHODS FOR USING THEM

Similar Documents

Publication Publication Date Title
JP2021514011A5 (https=)
AU2019283921B2 (en) Indole carboxamide compounds useful as kinase inhibitors
JP2021514400A5 (https=)
CA2860951C (en) Imidazopyrrolidinone compounds
RU2481346C2 (ru) Ингибиторы фосфатидилинозитол-3-киназы
RU2015106787A (ru) Замещенные пирролы, активные в качестве ингибиторов киназ
RU2015148189A (ru) ПРОИЗВОДНЫЕ 2-АМИДОПИРИДО[4, 3-d]ПИРИМИДИН-5-ОНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ WEE-1
RU2008129810A (ru) Противовирусные соединения
MXPA04008680A (es) Derivados de pirazol triciclicos, procedimientos para su preparacion y su uso como agentes anti-tumorales.
JP2016514134A (ja) Ｂｅｔブロモドメイン阻害剤およびこれを用いる治療方法
JP2014503566A5 (https=)
KR20170069199A (ko) 섬유 아세포 성장 인자 수용체 키나아제 억제제인 인다졸계 화합물 및 이의 제조와 응용
RU2002129557A (ru) Производные 8-хинолинксантина и 8-изохинолинксантина в качестве ингибиторов фосфоэстеразы pde5
JP2009543867A5 (https=)
RU2012111215A (ru) Гетероциклические соединения в качестве ингибиторов янускиназы
JP2007521287A5 (https=)
WO2005014572A1 (en) Pyrimidylpyrrole derivatives active as kinase inhibitors
RU2018102449A (ru) Производные пиразоло[1,5-a]триазин-4-амина, применимые в терапии
JP2021514398A5 (https=)
JP2006512366A5 (https=)
JP2021518379A5 (https=)
RU2006138606A (ru) Ингибиторы киназы
JP2021514399A5 (https=)
JP2003516994A5 (https=)
JP2017525734A5 (https=)